Pioglitazone price in India (2026)

There is no fixed public retail price for pioglitazone in India in the sources we track (most supply is hospital- or named-patient based). Use the Bangladesh list price as the benchmark: BDT 5.07–BDT 8.07 (US$0.04–US$0.07) per unit, about INR 3.953–INR 6.293 in INR per unit and INR 118.6–INR 188.78 per 30-unit month, before freight, customs duty and distributor margin.

Yes, but only through the rules of the Central Drugs Standard Control Organisation (CDSCO): India is the largest generic producer in the world but a section of the oncology and biologic market is still originator-priced. Indian generics of recent molecules appear only after the local patent position allows (India issues compulsory licences case by case), so availability of the newest molecules lags Bangladesh. Prices are quoted as MRP per pack in INR. Prescription medicines must move on a valid prescription through a licensed importer, pharmacy or hospital; personal-use imports need a named-patient / compassionate-use authorisation.

We cannot confirm the registration status of every individual generic brand in India. Central Drugs Standard Control Organisation (CDSCO) is the approving authority, and only products with a local product registration (or a special import authorisation) may be sold routinely. Ask your supplier for the local registration or import permit for the specific brand before you buy.

Bangladesh is a least-developed-country WTO member with a pharmaceutical patent exemption running to 2033, so local manufacturers can legally produce molecules that are still on patent elsewhere — and DGDA-registered list prices are public. That makes it the practical global floor price for on-patent targeted therapy and the benchmark used in import negotiations.